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Abstract
Photoreceptor cGMP phosphodiesterases (PDE6 family) are modular enzymes with each catalytic subunit containing two N-ter-
minal regulatory GAF domains, GAF A and GAF B. The GAF A domains contribute to dimerization of the PDE6 catalytic sub-
units and to binding of the inhibitory Pc subunits, and represent candidate sites for noncatalytic binding of cGMP. We performed a
mutational analysis of selected residues from the GAF A domain of cone PDEa 0 to identify the cGMP-binding pocket and delineate
the Pc-binding surface. Results of this analysis establish the noncatalytic cGMP-binding site within the PDE6 GAF A domain and
suggest that occupation of the pocket by cGMP is required for high-aﬃnity binding of Pc to the proximate contact surface.
 2004 Elsevier Ltd. All rights reserved.
Abbreviations: PDE, phosphodiesterase; PDE6, photoreceptor PDE; Pc, c-subunit of PDE6; PDE5, cGMP-binding, cGMP-speciﬁc PDE (PDE5
family); GAF domains, structural motifs present in cGMP-regulated PDE, adenylyl cyclases, and the E. coli protein Fh1A
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Phosphodiesterases of cyclic nucleotides are critical
enzymes modulating cellular levels of cAMP and cGMP.
Eleven families of PDEs have been identiﬁed in mamma-
lian tissues based on primary sequence, substrate selec-
tivity, and regulation (Beavo, 1995; Francis, Turko, &
Corbin, 2001). Photoreceptor rod and cone PDEs com-
prise the PDE6 family. Rod PDE6 is composed of two
large homologous catalytic a- and b-subunits of similar
size and two copies of a small inhibitory c-subunit
(Baehr, Devlin, & Applebury, 1979; Deterre, Bigay, For-
quet, Robert, & Chabre, 1988; Hurley & Stryer, 1982;
Lipkin et al., 1990). Cone PDE is a catalytic homodimer0042-6989/$ - see front matter  2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.visres.2004.05.013
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E-mail address: nikolai-artemyev@uiowa.edu (N.O. Artemyev).between two PDEa 0 subunits each complexed with a
cone-speciﬁc Pc subunit (Hamilton & Hurley, 1990;
Li, Volpp, & Applebury, 1990). PDE6s are the eﬀector
enzymes in the vertebrate visual transduction cascade.
The pool of the GTP-bound transducin-a (Gta) is gen-
erated from heterotrimeric Gtabc following its interac-
tion with photoexcited rhodopsin or cone pigments.
PDE6s are then activated by GtaGTP that interacts
with the holoenzyme and releases the inhibition exerted
by the Pc subunits (Arshavsky, Lamb, & Pugh, 2002;
Chabre & Deterre, 1989).
The catalytic domains of PDE6 of about 280 aa resi-
dues are located in the C-terminal part of the molecule
and are highly conserved among all known cyclic nu-
cleotide phosphodiesterases (Beavo, 1995). The N-term-
inal domains of PDE6 catalytic subunits contain two
structural motifs termed GAF domains (GAF A and
GAF B) because of their presence in cGMP-regulated
PDE, adenylyl cyclases, and the E. coli protein
Fh1A (Aravind & Ponting, 1997). In three of the
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PDE2, cGMP-binding/cGMP-speciﬁc PDE5, and
PDE6, noncatalytic binding of cGMP to the regulatory
N-terminal domains had been demonstrated experimen-
tally (Gillespie & Beavo, 1989; Martins, Mumby, & Bea-
vo, 1982; Thomas, Francis, & Corbin, 1990; Yamazaki,
Bartucca, Ting, & Bitensky, 1982). Noncatalytic cGMP-
binding has been shown to stimulate the catalytic activ-
ity of PDE2 and PDE5 (Martins et al., 1982; Rybalkin,
Rybalkina, Shimizu-Albergine, Tang, & Beavo, 2003).
In contrast, the functional signiﬁcance of the PDE6
GAF domains is not well understood. In PDE6, cGMP
bound to noncatalytic sites appears to enhance aﬃnity
of the interaction between Pc and the catalytic subunits,
but does not inﬂuence the catalytic activity independ-
ently of Pc binding. Reciprocally, Pc binding enhances
cGMP-binding aﬃnity to the GAF domains (Cote,
Bownds, & Arshavsky, 1994; Mou & Cote, 2001;
Yamazaki et al., 1982). Although the regions of noncat-
alytic cGMP binding in PDE2, PDE5, and PDE6 have
been approximated from sequence analyses and bio-
chemical experiments, until recently the exact locations
of the binding pockets have not been known. A solution
of the crystal structure of PDE2A GAF A-GAF B do-
mains provided a critical breakthrough by revealing
the cGMP-binding site within the PDE2 GAF B domain
and uncovering a novel cGMP-binding motif (Martinez
et al., 2002). Furthermore, the structure made possible
the prediction that the GAF A rather than GAF B do-
mains are the likely candidates for noncatalytic cGMP-
binding in PDE5 and PDE6 (Martinez et al., 2002).
Recent studies have supported this prediction for
PDE5 (Liu, Underwood, Li, Pamukcu, & Thompson,
2002; Sopory, Balaji, Srinivasan, & Visweswariah,
2003). However, the identity of noncatalytic binding
sites in PDE6 has not yet been established. Besides har-
boring potential cGMP-binding sites, the GAF A
domains of PDE6 have also been implicated in binding
Pc. Two regions of Pc are mainly involved in the inter-
action with the PDE6 catalytic subunits, the central
polycationic region (residues 21–45 of rod Pc) and the
Pc C-terminus. The C-terminus of Pc represents the
key inhibitory domain and apparently directly occludes
the catalytic cavity (Granovsky & Artemyev, 2000).
The polycationic region makes a major contribution to
the overall aﬃnity of Pc for PDE6 catalytic subunits
(Artemyev & Hamm, 1992; Mou & Cote, 2001). A
cross-linking study using a photoexcitable peptide probe
corresponding to the polycationic region of Pc revealed
incorporation of the probe into the GAF A domain of
rod PDE6a at residues Met138Gly139 (Muradov, Gra-
novsky, Schey, & Artemyev, 2002). This led us to hy-
pothesize that the positive cooperativity between
noncatalytic cGMP and Pc results from their binding
to the same regulatory domain. We carried out a muta-
tional analysis of potential cGMP- and Pc-contact resi-dues within the GAF A domain of cone PDEa 0 to
delineate the binding sites and elucidate the molecular
mechanism of their cooperativity.2. Materials and methods
2.1. Materials
[3H]cGMP was a product of Amersham Pharmacia
Biotech. All restriction enzymes were purchased from
NEB. AmpliTaq DNA polymerase was a product of
Applied Biosystems, and Pfu DNA polymerase was a
product of Stratagene. Polyclonal anti-His6 antibodies
were obtained from Santa Cruz. Zaprinast and all other
reagents were purchased from Sigma.
2.2. Mutagenesis of Chi16
The C-terminally His6-tagged PDE5/PDE6 Chi16
(Granovsky & Artemyev, 2000) was constructed as fol-
lows. The Chi16 sequence was ampliﬁed from the pFast-
BacHTb-Chi16 plasmid using a 5 0 primer containing an
RsrII site and a 3 0 primer containing His6-tag, a stop
codon, and a XhoI site. This sequence was then sub-
cloned into the RsrII/XhoI digested pFastBacHTb.
Mutations were introduced into Chi16 by PCR-directed
mutagenesis using a 5 0 primer coding desired substitu-
tion and a 3 0 primer containing the SacI site (aa
Glu248–Leu249). This PCR product was then extended
to the start of Chi16 using PCR with a 5 0 primer con-
taining RsrII site. Resulting PCR products were cut with
RsrII and SacI and ligated to similarly digested pFast-
BacHTb-Chi16. The sequences of all mutants were ver-
iﬁed by automated DNA sequencing at the University of
Iowa DNA Core Facility.
2.3. Expression and puriﬁcation of Chi16 and mutants
Generation of the recombinant bacmid DNAs, trans-
fection of Sf9 cells, and viral ampliﬁcations were carried
out according to the manufacturers recommendations
(Life Technologies, Inc.). For protein expression, Sf9
cell cultures (3·106 cells/ml) were infected with baculo-
viruses at MOI of 2–5. Cells were harvested by centrifu-
gation at 48 h after infection; washed with 20 mM
Tris–HCl buﬀer (pH 8.0) containing 150 mM NaCl
and 4 mMMgSO4, and processed immediately or stored
at 80 C until use. Sf9 cell pellets from 100 ml culture
were resuspended in 10 ml of 20 mM Tris–HCl buﬀer
(pH 8.0) containing 2 mM MgSO4, and one tablet of
Complete Mini protease inhibitor cocktail (Roche
Molecular Biochemicals). Cell lysates were obtained by
sonication with four 20-s pulses using a ﬂat tip attached
to a 550 Sonic Dismembrator (Fisher Scientiﬁc) and
cleared by centrifugation (100,000g, 90 min, 4 C).
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chromatography on a His-bind resin (Novagen) as de-
scribed earlier (Granovsky & Artemyev, 2000). Puriﬁed
proteins were dialyzed against 40% glycerol and stored
at 20 C.
2.4. cGMP-binding assay
Chi16 and its mutants were incubated on ice for 10
min in a volume of 150 ll of 30 mM Tris–HCl (pH
8.0), 50 mM NaCl, 1 mM EDTA, 5 mM 2-mercapto-
ethanol, and 0.1 mM zaprinast. These mixtures then
were added to tubes containing 50 ll [3H]cGMP
(100,000 cpm) and diﬀering concentrations of nonradio-
active cGMP. After 20 min incubation on ice, samples
were applied to wet 0.45 lm nitrocellulose membrane
ﬁlters, and were washed 5 times with 1 ml ice-cold
PBS buﬀer containing 1 mM EDTA. Dried ﬁlters were
dissolved in scintillation cocktail and were counted in
a scintillation counter. The data were ﬁt to equation
Y=Bmax*X/(Kd+X).
2.5. PDE activity assay
PDE activity was measured using [3H]cGMP as de-
scribed (Natochin & Artemyev, 2000). Brieﬂy, 0.1 nM
Chi16 or mutants were incubated in 80 ll of 20 mM
Tris–HCl (pH 8.0) buﬀer containing 50 mM NaCl, 1
mMMgSO4, and 2 mM 2-mercaptoethanol, 0.1 lm bac-
terial alkaline phosphatase, 5 lM [3H]cGMP (100,000
cpm) at 25 C. After addition of [3H]cGMP, the reaction
was allowed to proceed for 10 min, and was stopped by
the addition of AG1-X2 anion exchange resin (0.5 ml of
20% bed volume suspension). Samples were incubated
for 10 min at 25 C with occasional mixing and spun
at 9000g for 2 min. Aliquots of 0.25 ml were removed
for counting in a scintillation counter. To determine
Km values for cGMP, PDE activity was measured using
0.5–100 lM cGMP and the data were ﬁt to equation
Y=Vmax*X/(Km+X). To determine Ki values for Pc
and IC50 values for zaprinast, PDE activity was meas-
ured with 5 lM [3H]cGMP in the presence of increasing
concentrations of Pc or zaprinast. The Ki (IC50) values
were calculated by ﬁtting data to equation Y=
T (TB)/(1+10^ ((XLogKi) *Hill Slope)), where T
(top) is PDE activity in the absence of Pc (or zaprinast),
B (bottom) is PDE activity at an inﬁnite concentration
of Pc (or zaprinast), and X is the logarithm of total Pc
(or zaprinast) concentration.
2.6. Other methods
Western blot analysis of proteins was performed fol-
lowing SDS-PAGE in 10% gels. Chi16 and mutants
were detected using anti-His6 polyclonal antibodies
(Santa Cruz) (dilution 1:3000), anti-rabbit antibodiesconjugated to horseradish peroxidase (Sigma), and
ECL reagents (Amersham Biosciences). Protein concen-
trations were determined by the method of Bradford
(1976) using IgG as a standard. The molar concentra-
tions of Chi16 and mutants were calculated based on
the fraction of PDE protein in preparations and the
MW of 186.0 kDa for the catalytic dimers. The frac-
tional concentrations of PDE were determined by scan-
ning Coomassie Blue stained SDS gels and measuring
integrated densities of individual bands with Scion
Image software (v. Beta 4.0.2). A typical fraction of
Chi16 and mutants in partially puriﬁed preparations
was 20–30%.3. Results
3.1. Mutagenesis of potential Pc-contact residues within
GAF A domain of PDE6a 0
Identiﬁcation of PDE6a Met138Gly139 as the site of
speciﬁc cross-linking of Pc-21–45 to rod PDE6 suggests
that the polycationic region of Pc binds in the vicinity of
these residues (Muradov et al., 2002). Moreover, analy-
sis of inhibition chimeric PDE5/PDE6 enzymes by Pc
indicates that the interaction with Pc-21–45 is speciﬁc
to the GAF domains of photoreceptor PDEs (Granov-
sky & Artemyev, 2000). Therefore, only PDE6-con-
served residues that diﬀer with corresponding PDE5
residues have been considered for mutational analysis.
Additional criteria for the selection were a solvent acces-
sibility of >25% and a proximity of <15 A˚ to the
PDE6aMet138 counterpart, PDE6a 0Val135, using a
homology model of the PDE6a 0 GAF A domain (Fig.
1). The GAF B domain of PDE2 was used in the mode-
ling because it has higher degree of homology to the
PDE6 GAF A domain than the PDE2 GAF A domain
(Fig. 1A). Based on the above criteria, seven PDE6a 0
residues were targeted for substitutions by Ala: Asn100,
Asp126, Val130, Asp134, Val135, His158, and Phe162 (Fig.
1A and B). These mutations were introduced into the
improved template of the Pc-sensitive chimera Chi16
containing PDE6a 0 GAF domains (Granovsky & Arte-
myev, 2000). The improvement was in the C-terminal
position of His6-tag, which led to increased expression
levels using Baculovirus/Sf9 cell system and consistent
yields of mutant proteins following puriﬁcation over
His-Bind resin. All seven mutants were expressed at
comparable levels as determined by Western blotting
(Fig. 2A).
The catalytic properties (Table 1) of the mutant
PDEs were similar to those of Chi16 (Km 3.6 lM; kcat
7 s1) indicating that the substitutions within the GAF
A domain did not aﬀect the catalytic domain. Further-
more, the mutants displayed no signiﬁcant diﬀerences
in the IC50 values for inhibition by zaprinast, a PDE5/
Fig. 1. (A) Sequence alignment of the bovine PDE6 and PDE5 GAF A domains with the GAF B domain of mouse PDE2A. The a1 helices in GAF
A domains, which correspond to the connecting helix between GAF A and GAF B (Martinez et al., 2002), are omitted from the alignment and
modeling. Red arrow indicates position of the cross-linked residue PDE6aMet138 (Muradov et al., 2002) and its PDEa 0 counterpart Val135. Black
arrows indicate PDE6-speciﬁc residues selected for mutagenesis of PDE6a 0GAF A to identify Pc contacts: Asn100, Asp126, Val130, Asp134, His158, and
Phe162. Positions corresponding to cGMP-binding residues in the PDE2 GAF B domain are underlined (Martinez et al., 2002). Green arrows indicate
candidate cGMP-binding residues selected for mutagenesis of PDE6a 0GAF A. (B) A homology model of the PDE6a 0 GAF A domain was generated
with Swiss-PdbViewer (v. 3.7b2) and SWISS-MODEL (Schwede et al., 2003) using the coordinates of the PDE2A GAF B domain as a template
(Martinez et al., 2002) and the sequence alignment shown in Fig. 1A. A space-ﬁlling image is produced using RasMol (v. 2.6). Potential Pc-contact
residues in the vicinity of Val135 (red) (PDE6a 0 counterpart of PDE6aMet138) selected for mutagenesis are shown in blue. (For interpretation of the
references in colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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to noncatalytic sites in all seven mutants was intact, sup-
porting proper folding of the GAF domains (Table 1).
The Pc-inhibition tests, however, revealed that two out
of seven mutations, V130A and H158A, considerably
impaired the interaction with the inhibitory subunit
(Fig. 3, Table 1). The remaining substitutions had no
signiﬁcant eﬀect on the ability of Pc to inhibit Chi16
(Table 1).3.2. Identiﬁcation of the noncatalytic cGMP-binding
pocket of PDE6a 0
The novel cGMP-binding motif identiﬁed in the
PDE2 GAF B domain is comprised of 11 aa residues
(Martinez et al., 2002). The structural determinants of
the cGMP-binding pocket identiﬁed in the PDE2
GAF B domain are better preserved in the PDE6
GAF A domain. On this basis, the GAF A domain
Fig. 2. Immunoblot analysis of Chi16 mutants with Ala substitutions
of potential Pc-contact residues Asn100, Asp126, Val130, Asp134, Val135,
His158, and Phe162 (A) and cGMP-binding residues Ser92, Leu110,
Asp164, and Thr167 (B). Recombinant His6-tagged mutants were
expressed in Sf9 cells and partially puriﬁed using chromatography on a
His-Bind resin (Novagen) as described under ‘‘Experimental proce-
dures’’. Immunoblotting was performed using rabbit anti-His6 poly-
clonal antibodies.
Table 1
Properties of the GAF A domain mutants of Chi16
Km, lM Kcat, s
1 IC50 for zaprinast, nM Ki for Pc, nM Kd for cGMP, nM
Chi16 mutants with substitutions of potential Pc-contact residues
Chi16 3.6±0.4 7.0 94±15 0.40±0.02 37±3
N100A 3.8±0.5 4.9 87±9 0.62±0.1 37±6
D126A 4.0±0.5 9.1 95±11 0.61±0.07 30±3
V130A 3.6±0.4 4.6 124±17 8.5±1.0 44±9
D134A 3.2±0.5 4.3 97±6 1.0±0.1 29±6
V135A 2.8±0.4 5.6 105±10 0.77±0.13 23±3
H158A 4.1±1.0 4.2 91±8 4.0±1.0 28±4
F162A 3.6±0.5 9.5 79±13 0.47±0.06 22±4
Chi16 mutants with substitutions of potential cGMP-binding residues
S92A 4.3±0.5 6.7 123±18 0.38±0.06 75±4
L110A 4.0±0.5 4.2 107±18 11±3 84±6*
D164A 3.4±0.3 4.4 93±14 7±2 233±52*
T167A 3.0±0.4 9.8 126±10 0.45±0.1 33±8
*The maximal binding of cGMP to L110A and D164A was 55 and 45%, respectively.
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Fig. 3. Inhibition of Chi16, V130A and H158A by Pc. The activities of
Chi16 (j), V130A (.), and H158A (m) were determined in the
presence of 5 lM cGMP and increasing concentrations of Pc, and are
expressed as a percentage of the respective PDE activity in the absence
of Pc. The calculated Ki values (nM) for Chi16, V130A, and H158A
are 0.40±0.02, 8.5±1.0, and 4.0±1.0, respectively.
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binding site (Martinez et al., 2002). The alignment
of PDE6 GAF A domains with the PDE2 GAF B do-
main and the model of the PDE6a 0 GAF A domain
with cGMP docked in the anti-conformation (Figs. 1
and 6) were used to select candidate residues for non-
catalytic cGMP-binding. Six residues, Ser92, Leu110,
Asp164, Thr167, Thr171, and Met190, were selected to
potentially represent diﬀerent types of interactions
(hydrophobic contacts, hydrogen bonds) with diﬀerent
groups of cGMP (the guanine ring and ribose). Two
mutants, T171A and M190A, were expressed at signif-
icantly reduced levels in comparison to Chi16 and the
other mutants, suggesting important roles of these res-
idues in correct folding of the GAF A domains.
Although these mutants were catalytically active, they
displayed no detectable binding of noncatalytic cGMP(not shown). S92A, L110A, D164A, and T167A were
expressed comparably to Chi16 (Fig. 2B). The cata-
lytic characteristics of these mutant PDEs were not
considerably diﬀerent from those of Chi16 (Table 1).
The IC50 values for the inhibition of mutants by zap-
rinast were also similar (Table 1). In contrast, the
aﬃnity and stoichiometry of noncatalytic cGMP-bind-
ing were signiﬁcantly lower for two Chi16 mutants,
L110A and D164A (Fig. 4, Table 1). The Kd value
for cGMP-binding to L110A was 84 nM with the cal-
culated maximal binding of 55% of that for Chi16.
The impairment of cGMP-binding to D164A was even
more severe with the Kd value of 233 nM and the
maximal binding of 45%. Substitution of Ser92 had a
moderate eﬀect on the Chi16 aﬃnity for cGMP (Fig.
4), whereas the T167A mutation produced no change
(Table 1).
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Fig. 4. Noncatalytic cGMP binding to Chi16, S92A, L110A, and
D164A. Binding of cGMP to Chi16 and mutants was carried out for 20
min on ice using [H3]cGMP (100,000 cpm) and varying concentrations
of unlabeled cGMP. The bound cGMP was determined by the ﬁlter-
binding assay, and is expressed as a percentage of maximal noncat-
alytic cGMP binding to Chi16 (0.6 mol cGMP/mol PDE subunit).
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Fig. 5. Inhibition of Chi16, L110A, and D164A by Pc. The activities
of Chi16 (j), L110A (m), and D164A (.) were determined in the
presence of 5 lM cGMP and increasing concentrations of Pc, and are
expressed as a percentage of the respective PDE activity in the absence
of Pc. The calculated Ki values (nM) for Chi16, L110A, and D164A
are 0.40±0.02, 11±3, and 7±2, respectively.
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the GAF A domain impair the PDE inhibition by Pc
Identiﬁcation of the GAF A domain mutants with
diminished noncatalytic binding of cGMP allowed us
to test if these substitutions inﬂuenced the interaction
with Pc. The analysis of inhibition of PDE activity of
L110A and D164A by Pc demonstrated markedly in-
creased Ki values (Fig. 5). Two mutations, S92A and
T167A, did not signiﬁcantly alter the inhibition by Pc
(Table 1). In a reciprocal approach, we attempted to
investigate the potential eﬀects of Pc on noncatalytic
cGMP-binding to Chi16 and its mutants. However,
Chi16, unlike native cone PDE6, did not display strong
potentiation of cGMP-binding by Pc. The aﬃnity of
Chi16 for noncatalytic cGMP (Table 1) appears to be
signiﬁcantly higher than that of cone PDE (Granovskyet al., 1998), and only modest (15%) increases in the
binding of cGMP to Chi16 and D164A were detected
in the presence of 2 lM Pc (not shown).4. Discussion
The direct role of the noncatalytic cGMP-binding to
the GAF domains in regulating PDE catalytic activity
has been demonstrated for enzymes from the PDE2
and PDE5 families. The roles and mechanisms of
PDE6 GAF domains in regulation of the enzyme remain
largely obscure. Several factors contributed to the lack
of full understanding of the function of the PDE6
GAF domains. First, achieving an eﬀective expression
system for the wild-type PDE6 enzymes had been diﬃ-
cult (Piriev, Yamashita, Shih, & Farber, 2003; Qin &
Baehr, 1994) and mutagenesis of PDE6 residues has pri-
marily been performed using PDE5/PDE6 chimeras
(Granovsky & Artemyev, 2000; Granovsky et al.,
1998). Secondly, noncatalytic cGMP-binding by PDE6
is complex in that the binding properties of the rod
and cone enzymes are diﬀerent (Gillespie & Beavo,
1988, 1989). Furthermore, signiﬁcant variations had
been reported in cGMP-binding characteristics of mam-
malian and amphibian PDE6 (Gillespie & Beavo, 1989;
Yamazaki et al., 1982). Despite all the variations, the
key regulation mode––a positive cooperativity between
noncatalytic cGMP-binding and the binding of Pc––ap-
pears to be common for various PDE6 isoforms (Cote
et al., 1994; Mou & Cote, 2001; Yamazaki et al.,
1982). Pc binding enhances cGMP-binding aﬃnity for
the GAF domains. Reciprocally, an occupation of
GAF domains by cGMP increases the Pc aﬃnity for
the catalytic subunits. It has been suggested that a de-
crease in intracellular cGMP upon light stimulation
and/or light adaptation of photoreceptor cells may cause
dissociation of cGMP from the noncatalytic sites of
PDE6. A subsequent reduction in Pc aﬃnity for PDE6
could promote a concerted GAP action of RGS9 and
Pc on Gta, thereby accelerating the turnoﬀ of visual sig-
nal (Cote et al., 1994; Mou & Cote, 2001). Understand-
ing the mechanism of positive cooperativity between
noncatalytic cGMP and Pc may provide insights into
functional roles of the regulatory domains of PDE6.
Others and we have demonstrated that the polycationic
region of Pc is responsible for Pcs ability to enhance
cGMP aﬃnity for the PDE6 GAF domains (Granovsky
et al., 1998; Mou & Cote, 2001). Identiﬁcation of
PDE6a Met138Gly139 as the site of speciﬁc cross-linking
of Pc-21–45 to rod PDE6 suggests that the PDE6 GAF
A domains directly participate in binding of the polycat-
ionic region of Pc (Muradov et al., 2002). The interac-
tion of Pc-21–45 with the GAF A domains of PDE6
and the stimulatory eﬀect of Pc on noncatalytic
cGMP-binding is consistent with the GAF A domains
H. Muradov et al. / Vision Research 44 (2004) 2437–2444 2443being the functional cGMP-binding sites as predicted by
the structure of the PDE2 GAF domains (Martinez et
al., 2002). The mutational analysis of the PDE6a 0
GAF A domain in the contexts of chimeric PDE5/
PDE6 enzyme conﬁrmed that it contains the Pc-binding
site. The analysis also provided the ﬁrst experimental
evidence that the PDE6a 0 GAF A domain forms a bind-
ing pocket for noncatalytic cGMP. Mutations of two
potential cGMP-contact residues, Thr171 and Met190, re-
sulted in a total loss of the cGMP binding. From the
model of PDE6a 0 GAF A, both residues are predicted
to interact with the phospho-ribose moiety of cGMP
(Fig. 6). This ﬁnding would support the localization of
the cGMP-binding site. Yet, the folding defects for these
two mutants cannot be ruled out. However, characteri-
zation of two other mutants, L110A and D164A, estab-
lishes the identity of the binding pocket. These mutants
are comparable to Chi16 in terms of expression levels
and catalytic characteristics, but their noncatalytic
cGMP-binding was markedly reduced. Leu110 is likely
to make stacking hydrophobic interactions with the gua-
nine ring of cGMP, whereas Asp164 is in a position to
interact with both the guanine ring and the phospho-ri-
bose portions of cGMP (Fig. 6). Disruption of these
interactions is in agreement with the observed defects
in cGMP-binding. Substitution of Phe205 in PDE5, a
counterpart to Leu110 in Chi16, had also led to a severe
cGMP-binding defect in this related enzyme (Sopory et
al., 2003). Mutation of Ser92 resulted in a moderate de-Fig. 6. A homology model of the PDE6a 0 GAF A domain with bound
cGMP. cGMP was extracted from the structure of the PDE2 GAF B
domain and docked into the superimposed homology model of the
PDE6a 0 GAF A domain using Sybyl (v. 6.6, Tripos). The side chains
of Pc -contact residues Val130 and His158 (magenta) and cGMP-binding
residues Leu110, Asp164, Thr171, and Met190 (orange) are shown in
‘‘sticks’’ representation. (For interpretation of the references in colour
in this ﬁgure legend, the reader is referred to the web version of this
article.)crease of Chi16 aﬃnity for noncatalytic cGMP. Substi-
tution of Thr167, another potential contact residue for
cGMP, had no signiﬁcant eﬀect on the ligand binding.
Assuming analogous binding of cGMP to PDE2 and
PDE6, Thr167 of PDE6a 0 would make only a water-
mediated contact with the guanine ring, and thus, the
mutant phenotype is not surprising.
Identiﬁcation of the binding pocket for cGMP and
two Pc-interacting residues on the surface of the
PDE6a 0 GAF A domain allows a closer examination
of the spatial and structural relationships between the
two binding sites. The Pc contact residues appear to
be situated in remarkable proximity to the opening of
the cGMP-binding pocket. This ﬁnding supports the
hypothesis that the positive cooperativity between
cGMP and Pc observed in native PDE6 arises from di-
rect mutual stabilization of the binding sites. The
impairment of Pc-inhibition in the mutants lacking high
aﬃnity for noncatalytic cGMP reinforces this mecha-
nism. A molecule of cGMP is buried in the binding cav-
ity (Fig. 6), which presumably adopts a more open
conformation prior to binding the nucleotide. In all like-
lihood, the Pc polycationic region has a low aﬃnity for
the ‘‘empty’’ conformation of the GAF A domain. Bind-
ing of cGMP apparently leads to a conformational
switch in the GAF A domain thereby inducing the bind-
ing of Pc and further locking the ligand in place.References
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